{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:32:26Z","timestamp":1790573546569,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,7,13]],"date-time":"2027-07-13T00:00:00Z","timestamp":1815436800000},"content-version":"am","delay-in-days":346,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000182","name":"Medical Research and Materiel Command","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000182","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014039","name":"US Department of Defense Prostate Cancer Research Program","doi-asserted-by":"publisher","award":["W81XWH-08-1-0074"],"award-info":[{"award-number":["W81XWH-08-1-0074"]}],"id":[{"id":"10.13039\/100014039","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014039","name":"US Department of Defense Prostate Cancer Research Program","doi-asserted-by":"publisher","award":["W81XWH-16-PCRP-CCRSA"],"award-info":[{"award-number":["W81XWH-16-PCRP-CCRSA"]}],"id":[{"id":"10.13039\/100014039","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005440","name":"National Institutes of Health Center for Scientific Review","doi-asserted-by":"publisher","award":["P30 CA014520"],"award-info":[{"award-number":["P30 CA014520"]}],"id":[{"id":"10.13039\/100005440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005440","name":"National Institutes of Health Center for Scientific Review","doi-asserted-by":"publisher","award":["P50 CA269011"],"award-info":[{"award-number":["P50 CA269011"]}],"id":[{"id":"10.13039\/100005440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clgc.2026.102589","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T05:33:35Z","timestamp":1780119215000},"page":"102589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Overall Survival of Patients With PSA-Recurrent Prostate Cancer: Long-Term Analysis of a Randomized Phase 2 Trial of pTVG-HP DNA Vaccine Versus Placebo"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1471-6723","authenticated-orcid":false,"given":"Douglas G.","family":"McNeel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens C.","family":"Eickhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9819-1911","authenticated-orcid":false,"given":"Glenn","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2026.102589_bib0001","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0022-5347(01)64243-5","article-title":"Long-term results of radical retropubic prostatectomy in men with high grade carcinoma of the prostate","volume":"158","author":"Oefelein","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2026.102589_bib0002","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","article-title":"Natural history of progression after PSA elevation following radical prostatectomy","volume":"281","author":"Pound","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.clgc.2026.102589_bib0003","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/cncr.26437","article-title":"Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials","volume":"118","author":"Antonarakis","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2026.102589_bib0004","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clgc.2026.102589_bib0005","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102589_bib0006","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1056\/NEJMoa2510310","article-title":"Improved survival with enzalutamide in biochemically recurrent prostate cancer","volume":"394","author":"Shore","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102589_bib0007","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1200\/JCO.19.01701","article-title":"Phase II trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP [MVI-816]) in patients with progressive, nonmetastatic, castration-sensitive prostate cancer","volume":"37","author":"McNeel","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102589_bib0008","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1200\/JCO.2008.19.9968","article-title":"Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer","volume":"27","author":"McNeel","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102589_bib0009","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2395680","article-title":"Long-term follow up of patients treated with a DNA vaccine (pTVG-hp) for PSA-recurrent prostate cancer","volume":"20","author":"Tonelli","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.clgc.2026.102589_bib0010","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41391-024-00894-0","article-title":"Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment","volume":"28","author":"Freedland","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2026.102589_bib0011","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-01693","article-title":"National Cancer Institute's Working Group on biochemically recurrent prostate cancer: clinical trial design considerations","author":"Einstein","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102589_bib0012","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300251","article-title":"Enzalutamide and quality of life in biochemically recurrent prostate cancer","volume":"2","author":"Freedland","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.clgc.2026.102589_bib0015","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102589_bib0016","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1002\/cncr.24429","article-title":"Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer","volume":"115","author":"Higano","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2026.102589_bib0017","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1200\/JCO.2005.04.5252","article-title":"Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer","volume":"24","author":"Small","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102589_bib0018","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1634\/theoncologist.2010-0129","article-title":"Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression","volume":"15","author":"Madan","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2026.102589_bib0019","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.urology.2013.01.061","article-title":"Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial","volume":"81","author":"Schellhammer","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2026.102589_bib0020","series-title":"Presented at the 14th Annual Meeting of the Chemotherapy Foundation Symposium","article-title":"Defiing the optimal role of immunotherapy and chemotherapy: advanced prostate cancer patients who receive Sipuleucel-T (PROVENGE) followed by docetaxel derive the greatest survival benefit","author":"Petrylak","year":"2006"},{"key":"10.1016\/j.clgc.2026.102589_bib0021","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1158\/1078-0432.CCR-06-2937","article-title":"Granulocyte macrophage colony-stimulating factor\u2013secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer","volume":"13","author":"Small","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2026.102589_bib0022","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008848","article-title":"Sequence of androgen receptor-targeted vaccination with androgen deprivation therapy affects anti-prostate tumor efficacy","volume":"12","author":"Muralidhar","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"Suppl 7","key":"10.1016\/j.clgc.2026.102589_bib0023","doi-asserted-by":"crossref","first-page":"vii91","DOI":"10.1093\/annonc\/mdn473","article-title":"Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer","volume":"19","author":"Sternberg","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2026.102589_bib0024","doi-asserted-by":"crossref","first-page":"5162","DOI":"10.1158\/1078-0432.CCR-20-0945","article-title":"Multicenter phase I trial of a DNA vaccine encoding the androgen receptor ligand-binding domain (pTVG-AR, MVI-118) in patients with metastatic prostate cancer","volume":"26","author":"Kyriakopoulos","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2026.102589_bib0025","first-page":"147","article-title":"Cancer vaccines: can they improve survival?","volume":"30","author":"Dillman","year":"2015","journal-title":"Cancer Biother Radiopharm"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:28:15Z","timestamp":1785878895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326000893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1558767326000893"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102589","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overall Survival of Patients With PSA-Recurrent Prostate Cancer: Long-Term Analysis of a Randomized Phase 2 Trial of pTVG-HP DNA Vaccine Versus Placebo","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102589","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102589"}}